Core-009
核心009
基本信息
- 批准号:9784284
- 负责人:
- 金额:$ 0.2万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-12-01 至 2020-11-30
- 项目状态:已结题
- 来源:
- 关键词:AdultAdvanced Malignant NeoplasmBudgetsCancer CenterCatchment AreaCenter Core GrantsChildChildhoodClinical ResearchCollectionColorectalCommunitiesEnsureEpidemiologyFeesFormalinFreezingFundingGrantHealthHodgkin DiseaseHospitalsHumanInformed ConsentInstitutional Review BoardsLaboratoriesLeadershipMalignant NeoplasmsMalignant neoplasm of lungMethodologyNeuroblastomaNormal tissue morphologyParaffin EmbeddingPathologyPeer ReviewProcessReportingResearchResearch PersonnelResidual stateResource SharingResourcesScienceServicesStomachSurveillance ProgramTissue EmbeddingTissue ProcurementsTissuesTumor TissueUSC/Norris Comprehensive Cancer Center and HospitalUnderserved PopulationVulnerable Populationsarmbasecarcinogenesisinnovationmemberpopulation basedprogramsrepository
项目摘要
The Translational Pathology Core has been continuously under the leadership of Dr. Sue Ellen Martin since its
founding in 1998. This NCI-funded Shared Resource provides a single point of access for Cancer Center
members needing tissue procurement and banking services. The specific aims of the Core are to: 1) procure,
bank, process, track, and distribute both fresh/frozen and formalin-fixed, paraffin embedded (FFPE) normal
and tumor tissue biospecimens necessary for laboratory-based, epidemiological, and hospital-based clinical
studies being conducted by USC Norris Cancer Center members; 2) procure, maintain, and track discarded
FFPE tumor tissue blocks from local regional hospitals identified through the Cancer Surveillance Program
(CSP) for the population-based LA Residual Tissue Repository (RTR), which corresponds directly to the
catchment area; 3) ensure that all studies utilizing tissue have appropriate documented IRB approval and that
protected health information (PHI) is not released unless there is a signed written Informed Consent; and 4)
incorporate innovations in tissue procurement and banking methodology to meet investigator-led research. The
Core continues to have three components, or Arms: Adult, Pediatric and Population-Based. Together, these
Arms provide an integrated, single stop service.
Accomplishments during the project period include: 1) increased usage by Cancer Center members with peerreviewed
grants. In the most recent reporting year (FY 2013-2014), 91 Cancer Center members used the Core,
of which 53 (58%) had peer-reviewed funding. This is an increase of 140%, from the prior project period; 2)
higher chargebacks. User fees account for 27% of the total budget, up from 17% over the project period; and
3) increased collection and distribution of both fresh/frozen and FFPE tissues. This has contributed to
significant research advances by Cancer Center members in understanding of the mechanisms involved in
carcinogenesis, particularly in gastric, colorectal, urothelial and lung cancers, neuroblastoma and Hodgkin’s
lymphoma.
自成立以来,转化病理学核心一直由Sue Ellen Martin博士领导。
成立于1998年。这个由NCI资助的共享资源为癌症中心提供了一个访问点
需要组织采购和银行服务的成员。核心的具体目标是:1)采购,
库、处理、跟踪和分发新鲜/冷冻和福尔马林固定、石蜡包埋(FFPE)正常
实验室、流行病学和医院临床所需的肿瘤组织生物标本
研究正在进行的南加州大学诺里斯癌症中心成员; 2)采购,维护和跟踪丢弃
通过癌症监测计划确定的来自当地区域医院的FFPE肿瘤组织块
(CSP)对于基于人群的LA残留组织储存库(RTR),其直接对应于
集水区; 3)确保所有使用组织的研究都有适当的IRB批准文件,
除非有签署的书面知情同意书,否则不得发布受保护的健康信息(PHI);以及4)
结合组织采购和库存方法创新,以满足制药商领导的研究。的
核心仍然有三个组成部分,或武器:成人,儿科和人口为基础。所有这些
Arms提供综合的一站式服务。
在项目期间取得的成就包括:1)癌症中心成员使用同行评审
赠款。在最近的报告年度(2013-2014财年),91名癌症中心成员使用了核心,
其中53个(58%)获得了同行评审资金。这比上一个项目期增加了140%; 2)
更高的退款。使用费占总预算的27%,高于项目期间的17%;
3)增加新鲜/冷冻和FFPE组织的收集和分布。这有助于
癌症中心成员在理解参与的机制方面取得了重大研究进展,
致癌作用,特别是在胃癌、结肠直肠癌、尿路上皮癌和肺癌、神经母细胞瘤和霍奇金淋巴瘤中,
淋巴瘤
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PEGGY J Farnham其他文献
PEGGY J Farnham的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PEGGY J Farnham', 18)}}的其他基金
Characterization of a novel family of human transcription factors that bind at +240 downstream of the transcription start site.
结合在转录起始位点下游 240 处的新型人类转录因子家族的表征。
- 批准号:
10361502 - 财政年份:2020
- 资助金额:
$ 0.2万 - 项目类别:
Characterization of a novel family of human transcription factors that bind at +240 downstream of the transcription start site.
结合在转录起始位点下游 240 处的新型人类转录因子家族的表征。
- 批准号:
10589127 - 财政年份:2020
- 资助金额:
$ 0.2万 - 项目类别:
Development of a nuclease-mediated technology to validate chromatin hubs
开发核酸酶介导的技术来验证染色质中心
- 批准号:
8308770 - 财政年份:2012
- 资助金额:
$ 0.2万 - 项目类别: